Clinical Trials Logo

Hereditary Angioedema (HAE) clinical trials

View clinical trials related to Hereditary Angioedema (HAE).

Filter by:

NCT ID: NCT05819775 Recruiting - Clinical trials for Hereditary Angioedema (HAE)

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Start date: May 24, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

NCT ID: NCT05578417 Recruiting - Clinical trials for Hereditary Angioedema (HAE)

A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

PROSPECT
Start date: June 15, 2023
Phase:
Study type: Observational

The main aim of this study is to describe the characteristics of participants, check for number of hereditary angioedema (HAE) cases, their treatment and outcomes. Another aim is to check how the healthcare facilities were utilized for treatment. Participants' data will be taken from their medical records (charts), which were already collected as a part of their routine care between January 1, 2012, and January 1, 2022.

NCT ID: NCT05509569 Recruiting - Clinical trials for Hereditary Angioedema (HAE)

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Start date: August 24, 2022
Phase:
Study type: Observational

This study is a survey in Japan of Icatibant subcutaneous injection 30 mg syringe used to treat children or teenagers with acute attacks of hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Icatibant subcutaneous injection 30 mg syringe and to check if Icatibant subcutaneous injection 30 mg syringe improves acute attacks of HAE. During the study, pediatric participants with HAE will take Icatibant subcutaneous injection 30mg syringe according to their clinic's standard practice. The study doctors will check for side effects from Icatibant subcutaneous injection 30 mg syringe for 3 months.

NCT ID: NCT05489640 Recruiting - Clinical trials for Hereditary Angioedema (HAE)

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Start date: November 18, 2022
Phase:
Study type: Observational

The main aim of this study is to describe the treatment patterns, characteristics and outcomes of people with HAE who are currently receiving icatibant in the homecare setting in the United Kingdom (UK). Participants will be treated with icatibant according to their routine practice via homecare service for icatibant within the UK. Data will be directly collected from participants via study diaries and questionnaires. Participants will be contacted approximately every 90 days during study duration (this can occur via phone or as a face-to-face visit).

NCT ID: NCT05469789 Recruiting - Clinical trials for Hereditary Angioedema (HAE)

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

Start date: June 29, 2023
Phase:
Study type: Observational

The main aim of this study is to compare the HAE attack rate requiring on-demand treatment before and within 2 years after participants with HAE have been treated with lanadelumab. This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).

NCT ID: NCT05460325 Completed - Clinical trials for Hereditary Angioedema (HAE)

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Start date: June 22, 2022
Phase: Phase 3
Study type: Interventional

The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.

NCT ID: NCT05397431 Recruiting - Clinical trials for Hereditary Angioedema (HAE)

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Start date: May 30, 2022
Phase:
Study type: Observational

This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.

NCT ID: NCT05147181 Recruiting - Clinical trials for Hereditary Angioedema (HAE)

A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

CHOPIN
Start date: March 11, 2022
Phase:
Study type: Observational

The main aim of this study is to learn about how many persons with HAE type I or type II are attack-free when treated with lanadelumab in real life, how many attacks occur and how many of these attacks need rescue treatment and about the nature of HAE attacks. Participants will need to visit their doctor 5 times in total as part of this study. The visits are planned every 6 months. Participants will also be asked to fill out questionnaires as part of this study.

NCT ID: NCT04861090 Completed - Clinical trials for Hereditary Angioedema (HAE)

A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis

INTEGRATED
Start date: September 15, 2021
Phase:
Study type: Observational

The main aims of this study are to learn how many people with HAE Type I or Type II are attack-free when treated with lanadelumab in real life. This includes the number of people that are attack-free when lanadelumab is given every 2 and every 4 weeks. This study is about collecting existing data only; participants will not receive lanadelumab as part of this study. No new information will be collected during this study. Only data already available at the participant's doctor's office will be reviewed and collected for this study. Participants do not need to visit their doctor in addition to their normal visits.

NCT ID: NCT04583007 No longer available - Clinical trials for Hereditary Angioedema (HAE)

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Start date: n/a
Phase:
Study type: Expanded Access

The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent angioedema attacks. This expanded access program enables these participants with a high unmet medical need to continue receiving lanadelumab during the interim period between completion of either the SHP643-301 (NCT04070326; SPRING study) or the TAK-743-3001 (NCT04444895) study and potential licensure of lanadelumab for the respective age group and/or treatment.